MVMartin Vanderlaan

Martin Vanderlaan

*This is an algorithmically generated author record based on publicly available information.

Martin Vanderlaan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Michael Waldera‐Lupa

    Protagen Protein Services GmbH, Biotherapeutical Analytics, Dortmund, Germany

    1 shared publication
  • Feny Gunawan

    Department of Analytical Development and Quality Control, Genentech, 1 DNA Way, South San Francisco, CA, 94080

    1 shared publication
  • Heiner Falkenberg

    Protagen Protein Services GmbH, Biotherapeutical Analytics, Dortmund, Germany

    1 shared publication
  • Joey Michael Studts

    Department of Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Bioprocess Development Biologicals, Biberach, Germany

    1 shared publication
  • Judith Zhu‐Shimoni

    Department of Analytical Development and Quality Control, Genentech, 1 DNA Way, South San Francisco, CA, 94080

    1 shared publication
  • Kevin E. Van Cott

    Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE, 68588

    1 shared publication

Latest Publications

  • Mass spectrometric evaluation of upstream and downstream process influences on host cell protein patterns in biopharmaceutical products

    by Heiner Falkenberg, Daniel Michael Waldera‐Lupa, Martin Vanderlaan, Thomas Schwab, Kurt Krapfenbauer, Joey Michael Studts, Thomas Flad, Thomas Waerner

    For production of different monoclonal antibodies (mAbs), biopharmaceutical companies often use related upstream and downstream manufacturing processes. Such platforms are typically characterized regarding influence of upstream and downstream process (DSP) parameters on critical quality attributes (CQAs). CQAs must be monitored strictly by an adequate control strategy. One such process‐related CQA is the content of host cell protein (HCP) which is typically analyzed by immunoassay methods (e.g., HCP‐ELISA). The capacity of the immunoassay to detect a broad range of HCPs, relevant for the individual mAb‐production process should be proven by orthogonal proteomic methods such as 2D gel electrophoresis or mass spectrometry (MS). In particular MS has become a valuable tool to identify and quantify HCP in complex mixtures. We evaluate up‐ and DSP parameters of four different biopharmaceutical products, two different process variants, and one mock fermentation on the HCP pattern by shotgun MS analysis and ELISA. We obtained a similar HCP pattern in different cell culture fluid harvests compared to the starting material from the downstream process. During the downstream purification process of the mAbs, the HCP level and the number of HCP species significantly decreased, accompanied by an increase in diversity of the residual HCP pattern. Based on this knowledge, we suggest a control strategy that combines multi product ELISA for in‐process control and release analytics, and MS testing for orthogonal HCP characterization, to attain knowledge on the HCP level, clusters and species. This combination supports a control strategy for HCPs addressing safety and efficacy of biopharmaceutical products.


  • Experience with host cell protein impurities in biopharmaceuticals

    by Martin Vanderlaan, Judith Zhu‐Shimoni, Sansan Lin, Feny Gunawan, Thomas Waerner, Kevin E. Van Cott

    In the 40‐year history of biopharmaceuticals, there have been a few cases where the final products contained residual host cell protein (HCP) impurities at levels high enough to be of concern. This article summarizes the industry experience in these cases where HCP impurities have been presented in public forums and/or published. Regulatory guidance on HCP impurities is limited to advising that products be as pure as practical, with no specified numerical limit because the risk associated with HCP exposure often depends on the clinical setting (route of administration, dose, indication, patient population) and the particular impurity. While the overall safety and purity track record of the industry is excellent, these examples illustrate several important lessons learned about the kinds of HCPs that co‐purify with products (e.g., product homologs, and HCPs that react with product), and the kinds of clinical consequences of HCP impurities (e.g., direct biological activity, immunogenicity, adjuvant). The literature on industry experience with HCP impurities is scattered, and this review draws in to one reference documented examples where the data have been presented in meetings, patents, product inserts, or press releases, in addition to peer‐reviewed journal articles. © 2018 American Institute of Chemical Engineers Biotechnol. Prog. , 34:828–837, 2018


  • Open Access

    Flow cytometric analysis of erythrocyte populations in tn syndrome blood using monoclonal antibodies to glycophorin A and the Tn antigen

    by William L. Bigbee, Richard G. Langlois, Larry H. Stanker, Martin Vanderlaan, Ronald H. Jensen

    Flow cytometric analysis employing monoclonal antibodies to the Tn antigen and glycophorin A was used to characterize the erythrocyte populations present in blood samples from individuals with Tn syndrome. Four monoclonal antibodies specific for the Tn antigen, GalNAc monosaccharide, on human erythrocytes were obtained from a fusion of splenocytes from a Biozzi mouse immunized with red cells from a Tn individual. These monoclonal antibodies specifically recognize GalNAc monosaccharide sites located on the erythrocyte cell surface sialoglycoproteins, glycophorin A and glycophorin B, and do not bind to fixed normal red cells presenting the Neu-NAcα2-3Galβ1-3(NeuNAcα2-6)GalNAcα1-O-Ser(Thr) tetrasaccharide or to fixed neuraminidase-digested cells presenting the Gal-GalNAc disaccharide. The percentages of Tn-positive red cells in samples from six unrelated Tn donors ranged from 28 to 99%. Binding of the glycophorin A-specific monoclonal antibodies showed that the erythrocytes composing the Tn-negative fraction presented normal amounts of the M and N epitopes on glycophorin A. The presumed somatic mutational origin of Tn-positive cells was tested in blood samples from five normal donors; three possible Tn cells were observed after analysis of a total of 1.1 X 107 erythrocytes, suggesting that the frequency of such cells in normal individuals is > 1 X 10−6.